Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronic Acid as a Delivery Vehicle for Dexamethasone in Intractable Hearing Loss
NCT04766853Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of hyaluronic acid in hearing loss, noise-induced hearing loss (NIHL) and Meniere's disease (MD) (2 arms), sponsored by Seoul National University Hospital. Primary endpoints: Verification of tympanic membrane with endoscopy, Confirmation of inflammation and drug with CT imaging at 1 week and 1 more. Started Jul 2021; status: completed.
02
Drugs
hyaluronic acid
03
Conditions
hearing lossnoise-induced hearing loss (NIHL)Meniere's disease (MD)
Beyond the preview
Go deeper on NCT04766853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04766853.